Klarisa Rikova is a senior scientist at Cell Signaling Technology, Inc. (CST) in Danvers, Massachusetts.
[1] This approach to liquid chromatography-mass spectrometry (LC-MS/MS) included a probability score, or an "Ascore," which measures the probability of a correct phosphorylation site by measuring the presence of specific ions indicative of phosphorylation sites on a peptide sequence.
[1] Using this method, scientists at Cell Signaling Technology were able to generate pY antibodies that function to pull down phosphorylated tyrosine residues through immunoprecipitation.
Rikova utilized this phosphoproteomic technique with tissue samples from patients with non-small cell lung cancer (NSCLC) and found excess phosphorylation in the tumor cell lines and surveyed tyrosine kinase signaling in these cancer lines.
[2] Focusing on cell signaling and post-transcriptional modifications (PTMs) enabled this novel screening technique that identifies specific oncogenic mutations in patients.